Penumbra Reports Positive Clinical Results for THUNDERBOLT Stroke System

The THUNDER study, which enrolled 216 patients across 29 U.S. centers, met its primary performance goals by achieving successful reperfusion in 87.5% of cases. The device utilizes modulated aspiration to fatigue and ingest clots, a process that researchers noted is critical for achieving optimal functional recovery. In 70.4% of treated cases, clinicians reached the mTICI 2c-3 score, a benchmark associated with significantly improved patient outcomes.

Data from the trial highlighted operational efficiency, with a median time-to-revascularization of 20 minutes and a first-pass success rate of 64.8%. Safety metrics were equally notable, with serious procedure-related adverse events occurring in only 2.8% of participants. Donald Frei, a co-principal investigator of the study, emphasized that the system’s ability to reliably ingest clots while maintaining a low complication profile represents a meaningful advancement in mechanical thrombectomy. The THUNDERBOLT device has already secured FDA clearance and a CE Mark, positioning it as a new tool for neurointerventionalists managing complex stroke cases.